Insider · CIK 0001346824
Ra Capital Management, L.p.
ownerdirector
Files at ABOS (Acumen Pharmaceuticals, Inc.), CDTX (Cidara Therapeutics, Inc.), WVE (Wave Life Sciences, Inc.), FDMT (4D Molecular Therapeutics, Inc.), SPRY (ARS Pharmaceuticals, Inc.), SLDB (Solid Biosciences Inc.), CLYM (Climb Bio, Inc.), ACRV (Acrivon Therapeutics, Inc.), ETNB (89bio, Inc.), VOR (Vor Biopharma Inc.), ARTV (Artiva Biotherapeutics, Inc.), JANX (Janux Therapeutics, Inc.), TYRA (Tyra Biosciences, Inc.), MLYS (Mineralys Therapeutics, Inc.), SEPN (Septerna, Inc.), SION (Sionna Therapeutics, Inc.). First filing Oct 22, 2024, latest Sep 21, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
7 / 1
$262M bought, $22M sold
Where the trades landed
Last year at the 3 companies this insider has traded most, with each buy and sell on the bar it happened.
SION: Sionna Therapeutics, Inc.
SIONOct 9, 2026 · close 4.90
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
JANX: Janux Therapeutics, Inc.
JANXOct 9, 2026 · close 18.39
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
MLYS: Mineralys Therapeutics, Inc.
MLYSOct 9, 2026 · close 23.37
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | $22M 3,448,811 shares | -50% | - | |
| 54Moderate | Mineralys Therapeutics, Inc. | $17M 1,296,296 shares | +43% | - | |
| 43Moderate | JANXbuy Janux Therapeutics, Inc. | $25M 824,041 shares | +9% | - | |
| 58Moderate | Sionna Therapeutics, Inc. | $20M 1,125,000 shares | +19% | - | |
| 54Moderate | 89bio, Inc. | $50M 5,714,285 shares | +41% | - | |
| 51Moderate | Tyra Biosciences, Inc. | $20M 1,220,681 shares | +16% | - | |
| 58Moderate | Septerna, Inc. | $75M 4,170,000 shares | +246% | - | |
| 43Moderate | JANXbuy Janux Therapeutics, Inc. | $54M 1,200,000 shares | +15% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | WVE Wave Life Sciences, Inc. | AGrant or award Common Stockindirect: See footnotes | +10,700 | $0.00 | $0 | 39,515 | 4 d ago |
| Oct 5, 2026 | WVE Wave Life Sciences, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnotes | +64,000 | $0.00 | $0 | 64,000 | 4 d ago |
| Oct 2, 2026 | VOR Vor Biopharma Inc. | MOption exercise Common Stockindirect: See footnotes | +500 | $12.80 | $6,400 | 500 | 6 d ago |
| Oct 2, 2026 | VOR Vor Biopharma Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: See Footnotes | -500 | $0.00 | $0 | 0 | 6 d ago |
| Sep 28, 2026 | CLYM Climb Bio, Inc. | MOption exercise Common Stockindirect: See footnotes | +10,000 | $3.46 | $35k | 10,000 | 11 d ago |
| Sep 28, 2026 | CLYM Climb Bio, Inc. | MOption exercise Common Stockindirect: See footnotes | +10,000 | $3.00 | $30k | 20,000 | 11 d ago |
| Sep 28, 2026 | CLYM Climb Bio, Inc. | MOption exercise Common Stockindirect: See footnotes | +10,000 | $7.89 | $79k | 30,000 | 11 d ago |
| Sep 28, 2026 | CLYM Climb Bio, Inc. | MOption exercise Common Stockindirect: See footnotes | +40,000 | $1.29 | $52k | 70,000 | 11 d ago |
| Sep 28, 2026 | CLYM Climb Bio, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: See footnotes | -10,000 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | CLYM Climb Bio, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: See Footnotes | -10,000 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | CLYM Climb Bio, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: See Footnotes | -10,000 | $0.00 | $0 | 0 | 11 d ago |
| Sep 28, 2026 | CLYM Climb Bio, Inc. | MOption exercise Stock Option (Right to Buy)derivativeindirect: See Footnotes | -40,000 | $0.00 | $0 | 0 | 11 d ago |
| Sep 17, 2026 | SION Sionna Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -3,415,011 | $6.32 | $22M | 3,482,612 | 20 d ago |
| Sep 17, 2026 | SION Sionna Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnotes | -33,800 | $7.46 | $252k | 3,448,812 | 20 d ago |
| Sep 15, 2026 | TYRA Tyra Biosciences, Inc. | POpen-market purchase Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | +9,078,529 | $22.03 | $200M | 11,616,986 | 24 d ago |
| Sep 10, 2026 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivativeindirect: See Footnotes | +16,250 | $0.00 | $0 | 16,250 | 27 d ago |
| Sep 8, 2026 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivativeindirect: See Footnotes | +13,750 | $0.00 | $0 | 13,750 | 33 d ago |
| Jun 25, 2025 | SPRY ARS Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnotes | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Jun 24, 2025 | ARTV Artiva Biotherapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivativeindirect: See Footnotes | +13,750 | $0.00 | $0 | 13,750 | Jun 26, 2025 |
| Jun 13, 2025 | ACRV Acrivon Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnotes | +20,275 | $0.00 | $0 | 20,275 | Jun 17, 2025 |
| Jun 4, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Common Stockindirect: See footnotes | +12,800 | $0.00 | $0 | 12,800 | Jun 5, 2025 |
| Jun 4, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnotes | +19,500 | $0.00 | $0 | 19,500 | Jun 5, 2025 |
| Mar 13, 2025 | MLYS Mineralys Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +1,296,296 | $13.50 | $17M | 4,280,051 | Mar 17, 2025 |
| Mar 5, 2025 | JANX Janux Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +304,287 | $30.56 | $9.3M | 9,621,533 | Mar 7, 2025 |
| Mar 5, 2025 | JANX Janux Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +37,455 | $31.30 | $1.2M | 9,658,988 | Mar 7, 2025 |
| Mar 6, 2025 | JANX Janux Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +372,093 | $30.78 | $11M | 10,031,081 | Mar 7, 2025 |
| Mar 7, 2025 | JANX Janux Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +110,206 | $31.02 | $3.4M | 10,141,287 | Mar 7, 2025 |
| Feb 13, 2025 | MLYS Mineralys Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnote | +32,900 | $0.00 | $0 | 32,900 | Feb 24, 2025 |
| Feb 19, 2025 | SLDB Solid Biosciences Inc. | POpen-market purchase Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | +3,722,085 | $4.03 | $15M | 3,722,085 | Feb 21, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +5,021,990 | - | - | 5,900,779 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +527,444 | - | - | 869,651 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +2,222,084 | - | - | 2,222,084 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Common Stockindirect: See footnotes | +179,975 | - | - | 327,808 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +1,022,586 | $18.00 | $18M | 6,923,365 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +102,414 | $18.00 | $1.8M | 2,324,498 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Series Seed Preferred Stockderivativeindirect: See footnotes | -819,153 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Series Seed Preferred Stockderivativeindirect: See footnotes | -319,069 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Series Seed Preferred Stockderivativeindirect: See footnotes | -138,054 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -1,229,830 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -451,580 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -124,908 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -923,773 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,155,469 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -4,364,874 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | SION Sionna Therapeutics, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -1,091,219 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 3, 2025 | ETNB 89bio, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See footnotes | +56,400 | $0.00 | $0 | 56,400 | Feb 5, 2025 |
| Jan 30, 2025 | ETNB 89bio, Inc. | POpen-market purchase Common Stockindirect: See Footnotes | +5,714,285 | $8.75 | $50M | 19,554,319 | Feb 3, 2025 |
| Jan 3, 2025 | CDTX Cidara Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivativeindirect: See Footnotes | +22,200 | $0.00 | $0 | 22,200 | Jan 7, 2025 |
| Dec 30, 2024 | VOR Vor Biopharma Inc. | AGrant or award Common Stockindirect: See footnotes | +16,897,159 | - | - | 37,820,713 | Dec 30, 2024 |
| Dec 30, 2024 | VOR Vor Biopharma Inc. | AGrant or award Warrant (Right to Buy)derivativeindirect: See Footnotes | +21,121,449 | - | - | 21,121,449 | Dec 30, 2024 |
| Dec 9, 2024 | FDMT 4D Molecular Therapeutics, Inc. | JOther Common Stockindirect: See footnotes | -535,000 | $0.00 | $0 | 4,563,211 | Dec 10, 2024 |
| Dec 9, 2024 | FDMT 4D Molecular Therapeutics, Inc. | JOther Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | +535,000 | - | - | 3,610,000 | Dec 10, 2024 |
| Nov 26, 2024 | CDTX Cidara Therapeutics, Inc. | AGrant or award Common Stockindirect: See footnotes | +389,716 | $14.91 | $5.8M | 1,092,796 | Nov 29, 2024 |
| Nov 26, 2024 | CDTX Cidara Therapeutics, Inc. | AGrant or award Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | +1,286,786 | $14.91 | $19M | 1,286,786 | Nov 29, 2024 |
| Nov 14, 2024 | ETNB 89bio, Inc. | POpen-market purchase Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | +3,250,000 | $8.50 | $28M | 4,331,081 | Nov 18, 2024 |
| Nov 8, 2024 | TYRA Tyra Biosciences, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +1,220,681 | $16.25 | $20M | 8,697,956 | Nov 13, 2024 |
| Oct 28, 2024 | SEPN Septerna, Inc. | CConversion Common Stockindirect: See footnotes | +1,695,515 | - | - | 1,695,515 | Oct 30, 2024 |
| Oct 28, 2024 | SEPN Septerna, Inc. | CConversion Common Stockindirect: See footnotes | +1,130,343 | - | - | 1,130,343 | Oct 30, 2024 |
| Oct 28, 2024 | SEPN Septerna, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +3,828,400 | $18.00 | $69M | 5,523,915 | Oct 30, 2024 |
| Oct 28, 2024 | SEPN Septerna, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +341,600 | $18.00 | $6.1M | 1,471,943 | Oct 30, 2024 |
| Oct 28, 2024 | SEPN Septerna, Inc. | CConversion Series B Preferred Stockderivativeindirect: See Footnotes | -14,598,896 | - | - | 0 | Oct 30, 2024 |
| Oct 28, 2024 | SEPN Septerna, Inc. | CConversion Series B Preferred Stockderivativeindirect: See Footnotes | -9,732,596 | - | - | 0 | Oct 30, 2024 |
| Oct 18, 2024 | JANX Janux Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +1,200,000 | $44.75 | $54M | 9,317,246 | Oct 22, 2024 |
| Oct 18, 2024 | TYRA Tyra Biosciences, Inc. | JOther Common Stockindirect: See footnotes | -1,000,000 | - | - | 7,477,275 | Oct 22, 2024 |
| Oct 18, 2024 | TYRA Tyra Biosciences, Inc. | JOther Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | +2,358,457 | - | - | 1,000,000 | Oct 22, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.